Danaher Corporation
DHR Healthcare Medical - Diagnostics & Research NYSE
$195.50
$-6.50 (-3.22%)
Open: $200.00 | High: $200.50 | Low: $195.32 | Prev Close: $202.00
Market Cap: $138.25B
Volume: 3.2M | Avg: 3.9M
Last updated: March 09, 2026 at 02:01 AMInvestment Rating
Neutral
Overall Score: 60/100
Rating Breakdown:
Stock Score Analysis
Stock Score: 512
Comprehensive Quality Assessment
Component Breakdown:
Valuation Metrics
| P/E Ratio | 38.94 |
| P/B Ratio | 2.63 |
| P/S Ratio | 5.63 |
| EPS | $5.02 |
| Beta | 0.96 |
| Shares Outstanding | 707.14M |
| 52-Week High | $242.80 |
| 52-Week Low | $171.00 |
| SMA 50 | $222.86 |
| SMA 200 | $210.17 |
| Dividend Yield | 0.65% |
| Annual Dividend | $1.28 |
| Next Earnings | April 21, 2026 01:30 PM ET |
Financial Ratios
| Gross Margin | 60.9% |
| Operating Margin | 20.9% |
| Net Margin | 14.7% |
| ROE | 7.0% |
| ROA | 4.3% |
| Debt/Equity | 0.35 |
| Current Ratio | 1.87 |
| Quick Ratio | 1.51 |
Balance Sheet
| Total Assets | $83.46B |
| Total Liabilities | $30.93B |
| Total Equity | $52.53B |
|
|
|
| Cash | $4.62B |
| Total Debt | $18.42B |
| Net Debt | $13.80B |
Income Statement
| Revenue | $24.57B |
| Gross Profit | $14.97B |
| Operating Income | $5.14B |
| Net Income | $3.61B |
|
|
|
| EBITDA | $6.95B |
| Revenue/Share | $34.73 |
Cash Flow
| Operating CF | $6.42B |
| CapEx | $1.16B |
| Free Cash Flow | $5.26B |
|
|
|
| Book Value/Share | $74.27 |
| Tangible Book/Share | $-11.92 |
| Equity/Share | $74.27 |
Technical Indicators
| RSI (14) | 30.15 Neutral |
| MACD |
-5.85
Signal: -5.40
|
| Volatility | 26.07% |
| Trading Signal | Bearish |
Performance & Returns
| 1 Year | -0.46% |
| Sharpe Ratio | -0.05 Poor |
| Volatility (Ann.) | 27.62% Moderate |
| DHR (1Y) | -0.46% |
| S&P 500 (1Y) | +13.03% |
| Alpha (Excess Return) | -13.5% |
Sector Comparison (Healthcare)
| Metric | DHR | Sector Avg | Percentile |
|---|---|---|---|
| P/E Ratio | 38.94 | 27.44 | 77% |
| P/B Ratio | 2.63 | -19.57 | 45% |
| ROE (%) | 6.99% | -9.42% | 28% |
| Net Margin (%) | 14.71% | 9.21% | 62% |
| Stock Score | 512 | 544.0 | 30% |
| 1Y Return (%) | -0.46 % | +8.31 % | 42% |
📊 Historical Price Analysis (Last 200 Days)
Loading chart...
Technical Analysis
| Ticker | Close | SMA 5 | SMA 8 | SMA 13 | SMA 50 | SMA 200 | RSI (14) | MACD | Volatility (%) | Volume | Signal | SMA Decision |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DHR | $195.50 | $202.86 | $204.97 | $206.61 | $222.87 | $210.17 | 30.15 | -5.85 | 26.07% | 739843 | Strong Short | Bearish Stack |
Candlestick Patterns
There wasn't any recognizable pattern for the DHR stock
News Sentiment
| 📊 Ticker | 📰 Headline | 💭 Sentiment | 📡 Source | 🔗 URL |
|---|---|---|---|---|
| DHR | Arrowstreet Capital Limited Partnership Boosts Stock Position in Danaher Corporation $DHR | Neutral | defenseworld.net | Read More |
| DHR | Did Danaher Corporation Insiders Breach their Fiduciary Duties to Shareholders? | Neutral | prnewswire.com | Read More |
| DHR | Bank of Montreal Can Acquires 173,087 Shares of Danaher Corporation $DHR | Neutral | defenseworld.net | Read More |
| DHR | Danaher Corporation (DHR) Presents at TD Cowen 46th Annual Health Care Conference Transcript | Neutral | seekingalpha.com | Read More |
| DHR | APG Asset Management N.V. Acquires 13,967 Shares of Danaher Corporation $DHR | Neutral | defenseworld.net | Read More |
Recent Insider Trading
No recent insider trading data available for DHR
Company Information
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy. This segment also offers bioprocess technologies, consumables, and services; and filtration, separation, and purification technologies to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology, molecular, acute care, and pathology diagnostics products. This segment offers clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, industrial, and natural resource applications. This segment also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.
| CEO | Rainer Blair |
| Employees | 61000 |
| Country | US |
| IPO Date | 1978-12-29 |
| Exchange | NYSE |
| Website | https://www.danaher.com |
| Sector | Healthcare |
| Industry | Medical - Diagnostics & Research |
Similar Stocks (Healthcare - Medical - Diagnostics & Research)
Rating Metrics Explained
DCF Score (Discounted Cash Flow)
Measures the intrinsic value of the stock based on projected future cash flows. A higher score indicates the stock is undervalued relative to its DCF valuation.
ROE Score (Return on Equity)
Evaluates how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better profitability and management effectiveness.
ROA Score (Return on Assets)
Measures how efficiently a company uses its assets to generate profit. A higher ROA means better asset utilization and operational efficiency.
D/E Score (Debt-to-Equity)
Assesses the company's financial leverage and risk. Lower debt-to-equity ratios indicate less financial risk and better balance sheet health.
P/E Score (Price-to-Earnings)
Compares stock price to earnings per share. A lower P/E ratio may indicate the stock is undervalued, while a higher ratio could suggest overvaluation or growth expectations.
P/B Score (Price-to-Book)
Compares market price to book value per share. Lower P/B ratios may indicate undervaluation relative to the company's net asset value.
Rating Recommendations:
Each metric is scored on a scale of 1-5, where the scores are determined by comparing the company's performance against industry benchmarks and historical data:
-
Strong Buy (5/5): Excellent score - strong positive indicator
- The metric significantly outperforms industry averages (top 20% of companies)
- Indicates exceptional financial health or attractive valuation in that category
-
Buy (4/5): Good score - positive indicator
- Above-average performance (top 40% of companies)
- Shows strong fundamentals with room for improvement
-
Neutral (3/5): Average score - neutral indicator
- Performance in line with industry median (middle 20%)
- Neither significantly positive nor negative signal
-
Sell (2/5): Below average - negative indicator
- Below-average performance (bottom 40% of companies)
- Suggests weakness in this particular metric
-
Strong Sell (1/5): Poor score - strong negative indicator
- Significantly underperforms industry (bottom 20%)
- Indicates potential risk or overvaluation in that category